Navigation Links
TheraBiogen, Inc. Relocates Corporate Headquarters to New Jersey

NEW YORK, Dec. 5, 2011 /PRNewswire/ -- TheraBiogen, Inc. (OTC BB: TRAB), a manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies, cold and flu symptoms and migraine headaches, today announced the relocation of its corporate headquarters to New Jersey.

The new facility located at 4400 Route 9 South in Manalapan, New Jersey will accommodate the Company's current staff and enable further expansion for the Company's future growth.

Kelly Hickel, CEO of TheraBiogen, commented, "As the demand for our products continues to grow, we have decided to relocate our corporate offices to New Jersey where we will have the capacity to expand with lower operating costs and more flexibility."  He added, "It is an added benefit to be located in New Jersey, the heart of America's pharmaceutical and over the counter drug industry."

Thera Max is available for purchase in over twelve thousand locations including Rite-Aid, Food Lion, Hannaford Supermarkets, Discount Drug Marts, Big Y Supermarkets and others.  For more information on Thera Max visit our website at, our  Facebook page at or follow us on Twitter at

About TheraBiogen, Inc.TheraBiogen is a manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies, cold and flu symptoms and migraine headaches. The products are made from natural, homeopathic ingredients and contain no zinc, which has been identified as potentially causing nasal problems in other similar products on the market. For further information please visit

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risk that could cause actual performance and results of operations to differ materially from those anticipated. These risks are set forth in the Company's most recently filed form 10-K and Form 10-Q reports. TheraBiogen, Inc. assumes no obligation to update the statements contained in this release except as required by applicable securities laws disclosure rules.Company Contact: Public Relations Contact: Investor Contact:TheraBiogen, Inc. 

Megan Megale 

Boutcher & BoutcherKelly T. Hickel, CEO 

Megale Public Relations 

Aimee Boutcher732-294-8705 



SOURCE TheraBiogen, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Rochester Medical Implants Relocates to New Facility in Noblesville, IN
2. The Pittsburgh Life Sciences Greenhouse Relocates Therapeutics Company to Pittsburgh
3. Ferring Pharmaceuticals To Develop Major Corporate Center in Parsippany, New Jersey
4. White Smile Global Inc. Corporate Update on the White Smile Premier™ "At-Home" LED Teeth Whitening System and the White Smile Tooth Gloss™, Including Clinical Study, Product Manufacturing, and Distribution
5. Accuray Incorporateds CEO to Speak at Lazard Capital Markets 8th Annual Healthcare Conference and Stephens Fall Investment Conference
6. Abbott Honored With Scrip Award for Leadership in Corporate Social Responsibility
7. Champions Oncology, Inc. Appoints Executive Vice President and Chief Financial Officer to Management Team and Corporate Office Relocation
8. ZONARE Medical Systems Announces Appointment of PJ Ryland as Vice President of Business Development & Corporate Accounts
9. ViroPharma Incorporated Reports Third Quarter 2011 Financial Results
10. nContact, Inc. Launches New Corporate Websites
11. Accuray Incorporated to Report Financial Results for First Quarter of Fiscal 2012
Post Your Comments:
(Date:11/24/2015)... 2015  Thanks to a donor with a personal ... Center,s Sister Diane Grassilli Center for Women,s Health now ... San Francisco . Fred ... with a gift of $617,320 that allowed the Center ... Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, three-dimensional (3-D) mammography ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or ... today that the first patient has been enrolled in ... treatment for metastatic castration-resistant prostate cancer ("mCRPC"). ... --> the United States ... 1/2 clinical trial, ESSA intends to demonstrate the safety, ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... new market research report "Spine Biologics Market by Product Type ... Type (Anterior Cervical Discectomy and Fusion, Posterior Lumbar Interbody Fusion), ... by MarketsandMarkets, the global market was valued at $1.90 Billion ... 2020, at a CAGR of 4.4% during the forecast period ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Wimbledon ... programs, launches new Wimbledon Athletics Facebook page to educate the public, ... unsuspected cardiac abnormalities. About 2,000 people under the age of 25 die from ...
(Date:11/25/2015)... ... 25, 2015 , ... Smiles by Stevens is pleased to announce ... wrinkling. While many patients are aware of the benefits of Botox® in the treatment ... those suffering with discomfort, soreness, and pain as a result of Jaw Tension, TMJ ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... decades of music, friendships, and learning in its 65th Anniversary Brillianteen Revue, scheduled ... 5-6. , For 65 years, Brillianteen has been a treasured tradition ...
(Date:11/25/2015)... D.C. (PRWEB) , ... November 25, 2015 , ... Today, ... fatalities on our nation’s roadways has dropped below 10,000 for the first time since ... 10,076 in 2013. , According to data released by the National Highway Traffic Safety ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... I found that regular bras were incredibly uncomfortable," said an inventor from Bronx, ... bra." , She developed the patent-pending RECOVERY BRA for added comfort and support. ...
Breaking Medicine News(10 mins):